ArticuGrasp Trial: New Flexible Tool vs Standard Grasper for Lung Cancer Node Removal in Keyhole Chest Surgery

Jianxing He

Status: Completed

Conditions: Non-Small Cell Lung Cancer

Treatments: Device: Articulating lymph-node grasper (SurgeoFlex Grasp); Device: Arm 2 Intervention Name Traditional rigid endograsper

Study type: Interventional

Funder types: Other

Identifiers

NCT07201077

ES-2025-165-01

Details and patient eligibility

About

This study is testing whether a new, flexible surgical tool-the SurgeoFlex Grasp-makes keyhole chest operations for early-stage lung cancer easier, faster, and safer than the standard rigid tool used today.

What is the problem? In keyhole (uniportal) chest surgery, formally known as single-port video-assisted thoracoscopic surgery (VATS), surgeons reach the lung through one small incision between the ribs. Because the operating space is tight, the usual stiff instruments can bump into each other and into surrounding tissues. This difficulty can prolong lymph-node removal and increase the risk of complications.

What is being tested?

The trial compares two handheld tools:

SurgeoFlex Grasp (intervention): a slim, bendable grasper that can be steered around corners.

Traditional EndoGrasper (control): a straight, rigid grasper currently used as the standard.

Who is taking part? Approximately 100 adults with early-stage non-small-cell lung cancer (NSCLC) (tumours 3 cm or smaller) who are scheduled for keyhole surgery at The First Affiliated Hospital of Guangzhou Medical University.

What will happen?

Participants are allocated by randomisation into one of two groups:

SurgeoFlex group-surgeons use the new flexible tool. Control group-surgeons use the standard rigid tool. All other aspects of the operation, anaesthesia, and post-operative care remain identical for both groups.

What is measured? Lymphadenectomy time (duration required to remove the specified lymph nodes). Number of lymph nodes successfully removed. Frequency of surgical-instrument collisions or interference (instrument-clash events).

Surgeon workload during the operation (assessed with the National Aeronautics and Space Administration Task Load Index [NASA-TLX]).

Skin-incision length, pain scores (Visual Analogue Scale [VAS]), recovery time, infection rates, and overall cost.

Quality-of-life scores one month after surgery (European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 [EORTC QLQ-C30] and its lung-cancer module [EORTC QLQ-LC13]).

What is expected? The investigators expect the SurgeoFlex Grasp to shorten operative time, reduce instrument interference, lower surgeon stress, and accelerate recovery without increasing cost.

How will this help patients? If the new tool performs as anticipated, future patients undergoing keyhole lung-cancer surgery may experience shorter operations, smaller scars, less pain, and lower infection risk while still obtaining complete cancer-related lymph-node removal.

Where is the study taking place? The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

Contact for more information:

Clinical Research Management Committee 151 Yanjiang Road, Yuexiu District, Guangzhou 510120, China Email: [e-mail]

Enrollment: 100 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Eligibility Criteria

Inclusion Criteria

• Age 18-70 years, any sex
• BMI 18.5-30 kg/m²
• Newly diagnosed non-small-cell lung cancer with pre-operative clinical stage cT1-2N0-1M0
• Scheduled to undergo single-port video-assisted thoracoscopic lobectomy with systematic lymph-node dissection
• Major organ function sufficient for surgery
• Written informed consent provided

Exclusion Criteria

• Small-cell lung cancer or mixed-type lung cancer
• Tumor invasion of main bronchus, chest wall, diaphragm, or major mediastinal vessels
• Previous ipsilateral thoracic surgery or prior neoadjuvant chemotherapy, radiotherapy, targeted therapy, or immunotherapy
• Severe cardiopulmonary dysfunction (FEV₁ <50 % predicted or LVEF <40 %)
• Pregnant or breastfeeding women
• Participation in another interventional clinical trial

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

100 participants in 2 patient groups

SurgeoFlex Grasp (SFG)

Experimental group

Description:

Participants receive UVATS with SurgeoFlex Grasp for lymph-node dissection.

Treatment:

Device: Articulating lymph-node grasper (SurgeoFlex Grasp)

Traditional Endograsper (TER)

Active Comparator group

Description:

Participants receive UVATS with Traditional Endograsper for lymph-node dissection.

Treatment:

Device: Arm 2 Intervention Name Traditional rigid endograsper